Garcia V, Lara-Chica M, Cantarero I, Sterner O, Calzado MA, Munoz E. Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells. Oncotarget. 2016;7(4):4490–506.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Ca-Cancer J Clin. 2013;63(1):11–30.
Article
PubMed
Google Scholar
Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 1996;28(4):251–65.
Article
CAS
PubMed
Google Scholar
Richter E, Srivastava S, Dobi A. Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(2):114–8.
Article
CAS
PubMed
Google Scholar
Adhami VM, Aziz MH, Reagan-Shaw SR, Nihal M, Mukhtar H, Ahmad N. Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Mol Cancer Ther. 2004;3(8):933–40.
CAS
PubMed
Google Scholar
Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate. 1997;32(4):284–93.
Article
CAS
PubMed
Google Scholar
Liu AY. Differential expression of cell surface molecules in prostate cancer cells. Cancer Res. 2000;60(13):3429–34.
CAS
PubMed
Google Scholar
Fu YM, Yu ZX, Lin H, Fu X, Meadows GG. Selective amino acid restriction differentially affects the motility and directionality of DU145 and PC3 prostate cancer cells. J Cell Physiol. 2008;217(1):184–93.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37–40.
Article
CAS
PubMed
Google Scholar
Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24(1):21–44.
Article
CAS
PubMed
Google Scholar
Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004;23(16):2838–49.
Article
CAS
PubMed
Google Scholar
Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003;17(7):1263–93.
Article
CAS
PubMed
Google Scholar
Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S. Oncogenes and signal transduction. Cell. 1991;64(2):281–302.
Article
CAS
PubMed
Google Scholar
Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270(5240):1326–31.
Article
CAS
PubMed
Google Scholar
Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signal. 2003;15(5):463–9.
Article
CAS
PubMed
Google Scholar
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–84.
Article
CAS
PubMed
Google Scholar
Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–310.
Article
CAS
PubMed
Google Scholar
Herrero A, Pinto A, Colon-Bolea P, Casar B, Jones M, Agudo-Ibanez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizan EM, et al. Small molecule inhibition of ERK dimerization prevents tumorigenesis by RAS-ERK pathway oncogenes. Cancer Cell. 2015;28(2):170–82.
Article
CAS
PubMed
Google Scholar
Cho WC, Leung KN. In vitro and in vivo anti-tumor effects of Astragalus membranaceus. Cancer Lett. 2007;252(1):43–54.
Article
CAS
PubMed
Google Scholar
Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004;22(12):2489–503.
Article
CAS
PubMed
Google Scholar
Li X, Yang G, Li X, Zhang Y, Yang J, Chang J, Sun X, Zhou X, Guo Y, Xu Y, et al. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in chinese. PLoS One. 2013;8(4):e60338.
Article
CAS
PubMed
PubMed Central
Google Scholar
Son SH, Park KK, Park SK, Kim YC, Kim YS, Lee SK, Chung WY. Decursin and decursinol from Angelica gigas inhibit the lung metastasis of murine colon carcinoma. Phytother Res. 2011;25(7):959–64.
Article
CAS
PubMed
Google Scholar
Fang EF, Zhang CZ, Zhang L, Wong JH, Chan YS, Pan WL, Dan XL, Yin CM, Cho CH, Ng TB. Trichosanthin inhibits breast cancer cell proliferation in both cell lines and nude mice by promotion of apoptosis. PLoS One. 2012;7(9):e41592.
Article
CAS
PubMed
PubMed Central
Google Scholar
Choi YK, Cho SG, Woo SM, Yun YJ, Park S, Shin YC, Ko SG. Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling. Mediat Inflamm. 2014;2014:492173.
Google Scholar
Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE, Klotz LH. Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis. 2006;9(1):68–76.
Article
CAS
PubMed
Google Scholar
Seiler JA, Conti C, Syed A, Aladjem MI, Pommier Y. The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol. 2007;27(16):5806–18.
Article
CAS
PubMed
PubMed Central
Google Scholar
Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 2010;48(6):749–62.
Article
CAS
PubMed
PubMed Central
Google Scholar
Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A, Levy E, Goldwasser F, Panis Y, Soubrane O, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005;65(3):948–56.
CAS
PubMed
Google Scholar
Sullivan LB, Chandel NS. Mitochondrial reactive oxygen species and cancer. Cancer Metab. 2014;2:17.
Article
PubMed
PubMed Central
Google Scholar
Choi YK, Cho SG, Choi YJ, Yun YJ, Lee KM, Lee K, Yoo HH, Shin YC, Ko SG. SH003 suppresses breast cancer growth by accumulating p62 in autolysosomes. Oncotarget. 2016.
Choi EK, Kim SM, Hong SW, Moon JH, Shin JS, Kim JH, Hwang IY, Jung SA, Lee DH, Lee EY, et al. SH003 selectively induces p73dependent apoptosis in triplenegative breast cancer cells. Mol Med Rep. 2016;14(4):3955–60.
PubMed
Google Scholar
Choi HS, Kim MK, Lee K, Lee KM, Choi YK, Shin YC, Cho SG, Ko SG. SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2. Oncotarget. 2016;7(22):32969–79.
PubMed
PubMed Central
Google Scholar
Woo SM, Kim AJ, Choi YK, Shin YC, Cho SG, Ko SG. Synergistic effect of SH003 and doxorubicin in triple-negative breast cancer. Phytother Res. 2016;30:1817–23.
Article
CAS
PubMed
Google Scholar
Sainz RM, Lombo F, Mayo JC. Radical decisions in cancer: redox control of cell growth and death. Cancers. 2012;4(2):442–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Festuccia C, Gravina GL, Biordi L, D’Ascenzo S, Dolo V, Ficorella C, Ricevuto E, Tombolini V. Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate. 2009;69(14):1529–37.
Article
CAS
PubMed
Google Scholar
Di Lorenzo G, Tortora G, D’Armiento FP, De Rosa G, Staibano S, Autorino R, D’Armiento M, De Laurentiis M, De Placido S, Catalano G, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 2002;8(11):3438–44.
PubMed
Google Scholar
Carrion-Salip D, Panosa C, Menendez JA, Puig T, Oliveras G, Pandiella A, De Llorens R, Massaguer A. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol. 2012;41(3):1128–38.
CAS
PubMed
Google Scholar